This clinical trial is to determine the safety and effectiveness of an investigational
bladder cancer drug named "PLZ4-coated paclitaxel-loaded nanoscale micelle (PPM)." PPM is
tiny particles that contain the chemotherapy drug paclitaxel. PLZ4 is a molecule that can
possibly guide PPM to specifically target and deliver paclitaxel into and kill bladder cancer
cells. In this trial, PPM will be instilled into the bladder cavity to treat bladder cancer
that does not invade into the muscle layer of the bladder and that has failed the treatment
of another drug BCG. Up to 29 patients will be enrolled into the trial. The main goal of this
trial is to determine the dose of PPM for future clinical trials, assess the toxicity and
obtain preliminary data regarding its effectiveness.